Trial Profile
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 1360707 (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Pharmacokinetics
- Sponsors GSK
- 25 Jun 2011 Trial phase changed from II to I as reported by ClinicalTrials.gov.
- 09 Jul 2010 New trial record